Nucleic Acid Programmable Protein Arrays (NAPPA) for the Discovery of Autoantibodies in Osteoarthritis

Since a decade, the nucleic acid protein programmable array (NAPPA) technology has provided researchers with a high-throughput proteomic technique for deciphering immune signatures and screening for biomarkers, among other applications. In osteoarthritis (OA), the activation of proinflammatory pathways of innate immunity due to cellular stress response and cartilage degradation is now considered to be one of the pathophysiological drivers of the disease, perpetuating the catabolic process and the inflammation of the joint. Therefore, the identification of immunosignatures in OA would allow to detect autoantibodies (AAbs) as a new source of disease-specific biomarkers. Herein, we describe a proteomic strategy combining NAPPA and in situ protein expression coupled with enzyme-linked immunoassays (ELISA) to search for novel serum AAbs in OA.